Antibody Contract Manufacturing Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to antibodies, including a brief discussion on the historical evolution of this class of medical products. It highlights the different categories of antibodies, namely monoclonal antibodies, bispecific antibodies and polyclonal antibodies, their potential applications, and mechanisms of action (as therapeutic interventions). In addition, it includes information on the structure of an antibody and its isotypes. Further, the chapter features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry and its advantages.

Chapter 4 provides an overview of the antibody contract manufacturing landscape. It includes information on over 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the CMO, number of manufacturing facilities, as well as location of these facilities, type of antibody manufactured, types of expression systems being used, fill / finish operations and affiliations to regulatory agencies.

Chapter 5 features a company competitiveness analysis of key players engaged in this domain. The analysis compares companies on the basis of their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation). 

Chapter 6 features detailed profiles of industry players that offer contract manufacturing services at preclinical, clinical and commercial scale and have more than two manufacturing facilities. Each profile provides a brief overview of the company, its contract service offerings, manufacturing capabilities and facilities and an informed future outlook.

Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.

Chapter 8 presents a benchmark analysis, highlighting the capabilities of small, mid-sized and large companies in terms of their service portfolio. Further, the analysis allows companies to compare their existing capabilities within and beyond their respective (geography-based) peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in the time period 2013-2019 (till October). It provides a brief description on the various types of partnership models (which include manufacturing agreements, process development and manufacturing agreements, licensing agreements, acquisitions, joint ventures, service alliances and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of agreement, type of partnership, project scale and focus therapeutic area. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the recent expansions that have taken place in the antibody contract manufacturing industry, since 2017. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, facility expansion, new facility), type of antibodies (monoclonal antibodies, bispecific antibodies and polyclonal antibodies) and geographical location of the facility.

Chapter 11 features an analysis of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).

Chapter 12 features a detailed analysis of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 13 presents a detailed market forecast analysis, highlighting the likely growth of the antibody contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia).

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of antibody contract manufacturing market, under a SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the antibody CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of antibody CMOs.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Dietmar Katinger (Chief Executive Officer, Polymun Scientific), David C Cunningham (Director Corporate Development, Goodwin Biotechnology) and Claire Otjes (Assistant Marketing Manager, Batavia Biosciences).

Chapter 17 is an appendix that contains the list of companies that offer custom manufacturing services for different type of antibodies.

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies

3.6. Types of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies

3.7. Overview of Contract Manufacturing
3.8. Need for Outsourcing in the Biopharmaceutical Industry
3.9. Advantages of Outsourcing Manufacturing Services

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Antibodies Manufactured
4.2.7. Analysis by Expression Systems Used
4.2.8. Analysis by Fill / Finish Services Offered
4.2.9. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AGC Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Future Outlook

6.3. Aldevron
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Future Outlook

6.4. BioXcellence (Boehringer Ingelheim)
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Future Outlook

6.5. FUJIFILM Diosynth Biotechnologies
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Future Outlook

6.6. Lonza
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Future Outlook

6.7. Merck
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Manufacturing Facilities and Capabilities
6.7.4. Future Outlook

6.8. Novasep
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Manufacturing Facilities and Capabilities
6.8.4. Future Outlook

6.9. Samsung BioLogics
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Manufacturing Facilities and Capabilities
6.9.4. Future Outlook

6.10. Synthon
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Manufacturing Facilities and Capabilities
6.10.4. Future Outlook

7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
7.1. Chapter Overview
7.2. Small Molecule Drugs and Biologics
7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
7.2.2. Comparison of Key Specifications
7.2.3. Comparison of Manufacturing Processes
7.2.4. Comparison of Key Manufacturing-related Challenges

8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Region-wise Benchmarking
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia, Peer Group VII
8.3.8. Asia, Peer Group VIII

8.4. Concluding Remarks

9. PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnerships Models

9.3. Antibody Contract Manufacturing: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Antibody
9.3.5. Analysis by Project Scale
9.3.6. Analysis by Focus Therapeutic Area

9.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
9.3.8. Geographical Analysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wise Distribution

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Antibody Contract Manufacturers: List of Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Antibody
10.2.4. Analysis by Location of Manufacturing Facility
10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
10.2.6. Analysis of Most Active Players by Number of Expansions
10.2.7. Geographical Analysis
10.2.7.1. Country-wise Distribution

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Antibody Contract Manufacturers: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. DEMAND ANALYSIS
12.1 Chapter Overview
12.2 Assumptions and Methodology
12.3 Antibody Contract Manufacturing Market: Overall Annual Demand
12.3.1. Analysis by Scale of Operation
12.3.2. Analysis by Geography

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology

13.3. Overall Antibody Contract Manufacturing Market, 2020-2030
13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody
13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.7. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used

13.8. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography
13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030
13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies

13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations

13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
13.8.1.8. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations

13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030
13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies

13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations

13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
13.8.2.8. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations

13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030
13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies
13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies
13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies

13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations

13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations
13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations
13.8.3.8. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remarks

15. FUTURE OF THE ANTIBODY CMO MARKET
15.1. Chapter Overview
15.2. Outsourcing Activity Anticipated to Witness Significant Growth
15.3. Shift from One-time Contractual Engagements to Strategic Partnerships
15.4. Adoption of New and Innovative Technologies
15.5. Concluding Remarks

16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
16.3. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
16.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biopharma
16.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1 Historical Milestones Related to the Discovery of Antibodies
Figure 3.2 Structure of an Antibody
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Monoclonal Antibody Production
Figure 3.5 Symmetric and Asymmetric Bispecific Antibodies
Figure 3.6 Mechanism of Action of Bispecific Antibodies
Figure 3.7 Polyclonal Antibody Production
Figure 3.8 Applications of Polyclonal Antibodies
Figure 3.9 Types of Third Party Service Providers
Figure 4.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Antibody Contract Manufacturers: Distribution by Company Size
Figure 4.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Figure 4.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Figure 4.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Figure 4.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 5.1 Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
Figure 5.2 Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
Figure 5.3 Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
Figure 6.1 AGC Biologics: Service Portfolio
Figure 6.2 Aldevron: Service Portfolio
Figure 6.3 BioXcellence (Boehringer Ingelheim): Service Portfolio
Figure 6.4 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.5 Lonza: Service Portfolio
Figure 6.6 Merck: Service Portfolio
Figure 6.7 Novasep: Service Portfolio
Figure 6.8 Samsung BioLogics: Service Portfolio
Figure 6.9 Synthon: Service Portfolio
Figure 7.1 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Figure 7.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 7.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 8.1 Benchmark Analysis: Distribution by Region and Company Size
Figure 8.2 Benchmark Analysis: North America, Peer Group I
Figure 8.3 Benchmark Analysis: North America, Peer Group II
Figure 8.4 Benchmark Analysis: North America, Peer Group III
Figure 8.5 Benchmark Analysis: Europe, Peer Group IV
Figure 8.6 Benchmark Analysis: Europe, Peer Group V
Figure 8.7 Benchmark Analysis: Europe, Peer Group VI
Figure 8.8 Benchmark Analysis: Asia, Peer Group VII
Figure 8.9 Benchmark Analysis: Asia, Peer Group VIII
Figure 8.10 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 9.1 Partnerships: Distribution by Year of Partnership
Figure 9.2 Partnerships: Distribution by Type of Partnership
Figure 9.3 Partnerships: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships: Distribution by Type of Antibody
Figure 9.5 Partnerships: Distribution by Project Scale
Figure 9.6 Partnerships: Distribution by Focus Therapeutic Area
Figure 9.7 Partnerships: Most Active Players
Figure 9.8 Partnerships: Country-wise Distribution
Figure 9.9 Partnerships: Continent-wise Distribution
Figure 10.1 Recent Expansions: Distribution by Year of Expansion
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Antibody
Figure 10.4 Recent Expansions: Distribution by Type of Antibody and Expansion
Figure 10.5 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 10.6 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 10.7 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Figure 10.8 Recent Expansions: Most Active Players
Figure 10.9 Recent Expansions: Distribution by Local and International Expansions
Figure 11.1. Antibody Contract Manufacturing: Installed Global Capacity
Figure 11.2. Antibody Contract Manufacturing Capacity: Distribution by Company Size
Figure 11.3. Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 11.4. Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 12.1 Demand Analysis: Annual Demand for Antibodies
Figure 12.2 Demand Analysis: Annual Demand for Clinical Scale Operations
Figure 12.3 Demand Analysis: Annual Demand for Commercial Scale Operations
Figure 12.4 Demand Analysis: Annual Demand in North America
Figure 12.5 Demand Analysis: Annual Demand in Europe
Figure 12.6 Demand Analysis: Annual Demand in Asia
Figure 13.1 Overall Antibody Contract Manufacturing Market, 2020-2030
Figure 13.2 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Figure 13.3 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 13.4 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.5 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Figure 13.6 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 13.7 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 13.8 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.9 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.10 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.11 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.12 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.13 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.14 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.15 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.16 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 13.17 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.18 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.19 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.20 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.21 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.22 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.23 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.24 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.25 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Figure 13.26 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.27 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.28 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.29 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.30 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.31 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.32 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.33 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 14.1 Antibody Contract Manufacturing: SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Table

Table 3.1 Key Features of Antibody Isotypes
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Important Target Classes
Table 3.3 List of Approved Monoclonal Antibodies
Table 3.4 Differences between Monoclonal and Polyclonal Antibodies
Table 4.1 List of Antibody Contract Manufacturers
Table 4.2 Antibody Contract Manufacturers: Information on Type of Antibodies Manufactured
Table 4.3 Antibody Contract Manufacturers: Information on Scale of Operation
Table 4.4 Antibody Contract Manufacturers: Information on Expression Systems Used
Table 4.5 Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
Table 4.6 Antibody Contract Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Overview of Manufacturing Capabilities
Table 6.3 AGC Biologics: Future Outlook
Table 6.4 Aldevron: Company Overview
Table 6.5 Aldevron: Overview of Manufacturing Capabilities
Table 6.6 Aldevron: Future Outlook
Table 6.7 BioXcellence (Boehringer Ingelheim): Company Overview
Table 6.8 BioXcellence (Boehringer Ingelheim): Overview of Manufacturing Capabilities
Table 6.9 BioXcellence (Boehringer Ingelheim): Future Outlook
Table 6.10 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.11 FUJIFILM Diosynth Biotechnologies: Overview of Manufacturing Capabilities
Table 6.12 FUJIFILM Diosynth Biotechnologies: Future Outlook
Table 6.13 Lonza: Company Overview
Table 6.14 Lonza: Overview of Manufacturing Capabilities
Table 6.15 Lonza: Future Outlook
Table 6.16 Merck: Company Overview
Table 6.17 Merck: Overview of Manufacturing Capabilities
Table 6.18 Merck: Future Outlook
Table 6.19 Novasep: Company Overview
Table 6.20 Novasep: Overview of Manufacturing Capabilities
Table 6.21 Novasep: Future Outlook
Table 6.22 Samsung BioLogics: Company Overview
Table 6.23 Samsung BioLogics: Overview of Manufacturing Capabilities
Table 6.24 Samsung BioLogics: Future Outlook
Table 6.25 Synthon: Company Overview
Table 6.26 Synthon: Overview of Manufacturing Capabilities
Table 6.27 Synthon: Future Outlook
Table 7.1 Comparison of Strengths and Weaknesses of Small Molecules and Biologics
Table 7.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 8.1 Benchmark Analysis: Peer Groups
Table 9.1 Antibody Contract Manufacturing: List of Partnerships, 2013-2019
Table 9.2 Antibody Contract Manufacturing Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
Table 10.1 Antibody Contract Manufacturing: List of Expansions, 2017-2019
Table 10.2 Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
Table 14.1 Patent Approval Information of Best-selling Biologics
Table 17.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Table 17.2 Antibody Contract Manufacturers: Distribution by Company Size
Table 17.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Table 17.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 17.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 17.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 17.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Table 17.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Table 17.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Table 17.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations /
Table 17.11 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Table 17.12 Partnerships: Distribution by Year of Partnership
Table 17.13 Partnerships: Distribution by Type of Partnership
Table 17.14 Partnerships: Distribution by Year and Type of Partnership
Table 17.15 Partnerships: Distribution by Type of Antibody
Table 17.16 Partnerships: Distribution by Project Scale
Table 17.17 Partnerships: Distribution by Focus Therapeutic Area
Table 17.18 Partnerships: Most Active Players
Table 17.19 Partnerships: Country-wise Distribution
Table 17.20 Recent Expansions: Distribution by Year of Expansion
Table 17.21 Recent Expansions: Distribution by Type of Expansion
Table 17.22 Recent Expansions: Distribution by Type of Antibody
Table 17.23 Recent Expansions: Distribution by Type of Antibody and Expansion
Table 17.24 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 17.25 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 17.26 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Table 17.27 Recent Expansions: Most Active Players
Table 17.28 Recent Expansions: Distribution by Local and International Expansions
Table 17.29 Antibody Contract Manufacturing: Installed Global Capacity
Table 17.30 Antibody Contract Manufacturing Capacity: Distribution by Company Size
Table 17.31 Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 17.32 Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 17.33 Demand Analysis: Annual Demand for Antibodies
Table 17.34 Demand Analysis: Annual Demand for Clinical Scale Operations
Table 17.35 Demand Analysis: Annual Demand for Commercial Scale Operations
Table 17.36 Demand Analysis: Annual Demand in North America
Table 17.37 Demand Analysis: Annual Demand in Europe
Table 17.38 Demand Analysis: Annual Demand in Asia
Table 17.39 Overall Antibody Contract Manufacturing Market, 2020-2030
Table 17.40 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Table 17.41 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Table 17.42 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 17.43 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Table 17.44 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Table 17.45 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Table 17.46 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Table 17.47 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.48 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.49 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.50 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.51 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.52 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.53 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.54 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Table 17.55 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Table 17.56 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.57 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.58 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.59 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.60 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.61 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.62 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.63 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Table 17.64 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Table 17.65 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.66 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.67 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.68 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.69 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.70 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.71 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. AbbVie Contract Manufacturing
2. Abcuro
3. Abdi Ibrahim
4. A-Bio Pharma
5. ABL
6. ABL Bio
7. Absolute Antibody
8. Abzena
9. AC Immune
10. Acticor Biotech 
11. Actinium Pharmaceuticals
12. Adagene
13. Affinita Biotech
14. Affinity Life Sciences
15. AGC Biologics
16. Ajinomoto Althea
17. Alcami
18. Aldevron
19. Alethia Biotherapeutics
20. Allele Biotechnology & Pharmaceuticals
21. Alligator Bioscience
22. Alvotech
23. Annular Biotech
24. Antibodies Incorporated
25. Antibody Production Services (division of Life Science Group)
26. Arabio
27. Arcus Biosciences
28. argenx
29. ASKA Biotech
30. ASLAN Pharmaceuticals
31. AURA Biotechnologies 
32. AutekBio
33. Avid Bioservices
34. Avioq
35. Axcellerate Pharma
36. Batavia Biosciences
37. Baxter BioPharma Solutions
38. Bayer
39. Baylor Scott & White Research Institute
40. BeiGene
41. Bharat Serums and Vaccine
42. BIBITEC
43. BINEX
44. BioInvent International
45. BioLineRx
46. Biomay
47. Biomedical Advanced Research and Development Authority (BARDA)
48. BiosanaPharma
49. Biosynergy EUROPE
50. BioTechnique
51. Biovian
52. BioVolutions
53. BioXcellence (Boehringer Ingelheim)
54. BJ Bioscience
55. Brii Biosciences
56. Bristol-Myers Squibb
57. Bruker
58. Calypso Biotech
59. CANbridge
60. Capralogics
61. Catalent
62. Catalent Biologics
63. Cell Culture Company
64. Cell Essentials
65. Celonic
66. Center of iPS Cell Research and Application, Kyoto University
67. Cerbios-Pharma
68. Changchun High & New Technology Industry
69. ChemPartner
70. Chiome Bioscience
71. CinnaGen 
72. Citryll
73. CMAB Biopharma
74. CMC Biologics
75. Cobra Biologics
76. Compugen
77. Cook Pharmica
78. Creative Biolabs
79. CytoDyn
80. Cytovance® Biologics
81. DaTaMabs
82. Diatec Monoclonals
83. DM Bio
84. Dyax 
85. Effimune
86. EirGenix
87. Emergent BioSolutions
88. Enzene Biosciences
89. Etinpro
90. EuBiologics
91. Eurofins CDMO
92. Eurogentec
93. exonbio
94. FairJourney Biologics
95. Faron Pharmaceuticals
96. Forty Seven
97. F-star
98. FUJIFILM Diosynth Biotechnologies
99. GlaxoSmithKline
100. Glenmark
101. Goodwin Biotechnology
102. GTP Technology
103. HALIX 
104. Harbour BioMed
105. Hong Kong Institute of Biotechnology
106. Horizon Pharma
107. IBC Generium
108. IDT Biologika
109. I-Mab Biopharma
110. Immune Pharmaceuticals
111. Inno Biologics 
112. InVivo Biotech
113. JHL Biotech
114. JSR
115. KBI Biopharma
116. Kemwell Biopharma
117. KUBio (a manufacturing unit of GE Healthcare)
118. LakePharma
119. LAMPIRE Biological Laboratories
120. Laureate Biopharmaceutical Services
121. LFB Biomanufacturing
122. Lipum
123. Lonza
124. Lupin
125. Mabion
126. MabPlex
127. MAbSilico
128. Mab-Venture Biopharma
129. MacroGenics
130. Maine Biotechnology Services
131. MassBiologics
132. Medicago
133. MedImmune
134. Medix Biochemica
135. Menarini Biotech
136. Merck
137. Meridian Life Science
138. Merus
139. Mologic
140. MorphoSys 
141. Mycenax Biotech
142. Nitto Avecia Pharma Services
143. Northway Biotechpharma
144. Novasep
145. NovoCodex Biopharmaceuticals
146. Omeros
147. OncoQuest
148. OncoSynergy
149. OncoVent
150. OsoBio
151. Pall
152. Pamlico Biopharma
153. Paragon Bioservices (a unit of Catalent Biologics)
154. Particle Sciences (a Lubrizol Company)
155. Pharmedartis
156. Pierre Fabre
157. Pionyr Immunotherapeutics
158. Piramal Pharma Solutions
159. PMI BioPharma Solutions
160. Polymun Scientific
161. Powerway Biotech
162. Praxis Pharmaceutical
163. Precision Biologics 
164. Premas Biotech
165. Prestige BioPharma
166. ProBioGen
167. PX'Therapeutics
168. Radimmune Therapeutics
169. ReliaTech
170. Rentschler Biopharma
171. Richter-Helm BioLogics
172. River Vision Development
173. RuiYi
174. Samsung BioLogics
175. Sandoz (a Novartis division)
176. Sanofi
177. SDIX
178. Selexis
179. Selexys Pharmaceuticals (acquired by Novartis)
180. Siam Bioscience
181. Siegfried
182. Sun Pharmaceutical
183. Surface Oncology 
184. Suzhou Kintor Pharmaceuticals
185. Symbiosis Pharmaceutical Services
186. Symphogen
187. Syngene (a subsidiary of Biocon)
188. Synthelis
189. Synthon
190. Takara Bio
191. The Native Antigen
192. Therapure Biopharma (Therapure Biomanufacturing)
193. Thermo Fisher Scientific
194. Tizona Therapeutics
195. Tmunity Therapeutics
196. Toyobo Biologics 
197. Translational Sciences
198. Trellis Bioscience
199. University College London
200. University of Toyama 
201. Vibalogics
202. Vivoryon Therapeutics
203. Wacker Biotech 
204. Waisman Biomanufacturing
205. WuXi AppTec
206. WuXi Biologics
207. Xpress Biologics
208. Zymeworks